Storytelling to Support Blood Thinner Use in Atrial Fibrillation
Tests a storytelling program to help Black adults with atrial fibrillation keep taking blood thinners.
Plain-language title generated from the registry record
Registry title: Storytelling for Reducing Gap in Anticoagulation Use in African Americans With Atrial Fibrillation
Key facts
- Where
- Ann Arbor, Jacksonville, and Worcester, United StatesSee the 4 sites
Where in United States
- University of Michigan Medical SchoolAnn Arbor, United StatesNo longer taking part
- Luis Ortega PazJacksonville, United StatesNo longer taking part
- DecentralizedWorcester, United StatesNo longer taking part
- UMass Chan Medical SchoolWorcester, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Massachusetts, Worcester
- Trial code
- NCT05997914
- Record updated
- 13 April 2026
- Original description
The overall goal of this study is to evaluate the effectiveness of a previously developed storytelling intervention on anticoagulation (AC) initiation/persistence in African American and Black patients with atrial fibrillation/flutter. The investigators hope to gain knowledge that may help treat atrial fibrillation or flutter and lower stroke and adverse cardiovascular event risks for African American and Black patients by increasing the use of blood thinning medications known as anticoagulants.Read full original descriptionShow less
Storytelling for Reducing Gap in Anticoagulation Use in African Americans With Atrial Fibrillation Randomized Trial (STORY-AF Trial)
The overall goal of this study is to evaluate the effectiveness of a previously developed storytelling intervention on anticoagulation (AC) initiation/persistence in African American and Black patients with atrial fibrillation/flutter. The investigators hope to gain knowledge that may help treat atrial fibrillation or flutter and lower stroke and adverse cardiovascular event risks for African American and Black patients by increasing the use of blood thinning medications known as anticoagulants.
Inclusion: African-American patients aged 18 or older with elevated stroke risk (CHA2DS2-VASc ≥2 for men and ≥3 for women) who are not currently on anticoagulation (AC) but for whom a cardiology provider or primary care provider at the two study sites recommended AC recently.
Exclusion: Patient without a visit with a primary care provider, cardiovascular medicine specialist, or ambulatory care provider in the previous one year; Patients with left atrial appendage surgery or device, hospice status, ongoing bleeding, and intracranial bleeding in intralobar territory; Non-African American and other non-Black patients under the age of 18 patients without an ICD-10 diagnostic code consistent with AF or atrial fibrillation or atrial flutter; Patient who is pregnant or a prisoner.